Hydroxylation of diverse flavonoids by CYP450 BM3 variants: Biosynthesis of eriodictyol from naringenin in whole cells and its biological activities

Microbial Cell Factories

Volumn 15, Issue 1, 2016, Pages

  Chu, Luan Luong ^a   Pandey, Ramesh Prasad ^a   Jung, Narae ^a   Jung, Hye Jin ^a   Kim, Eun Hee ^b   Sohng, Jae Kyung ^a  

^a SunMoon University   (South Korea)

^b Korea Basic Science Institute (KBSI)   (South Korea)

Author keywords

Cytochrome P450 BM3; Flavonoids; Hydroxylation; Monooxygenase

Indexed keywords

CYTOCHROME P450 BM3; ERIODICTYOL; FLAVANONE; FLAVONOID; HESPERETIN; NARINGENIN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CULTURE MEDIUM; CYTOCHROME P450; FLAVANONE DERIVATIVE; RECOMBINANT PROTEIN;

ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACILLUS MEGATERIUM; BIOLOGICAL ACTIVITY; BIOSYNTHESIS; BIOTRANSFORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; MUTANT; NONHUMAN; WILD TYPE; BACTERIUM; BIOREACTOR; CHEMISTRY; CULTURE MEDIUM; DRUG EFFECTS; ENZYMOLOGY; GENETICS; KINETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MUTATION; OXIDATION REDUCTION REACTION; TUMOR CELL LINE;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACILLUS MEGATERIUM; BACTERIA; BIOREACTORS; BIOTRANSFORMATION; CELL LINE, TUMOR; CULTURE MEDIA; CYTOCHROME P-450 ENZYME SYSTEM; FLAVANONES; HUMANS; HYDROXYLATION; KINETICS; MICROBIAL SENSITIVITY TESTS; MUTATION; OXIDATION-REDUCTION; RECOMBINANT PROTEINS;

EID: 84988358717     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/s12934-016-0533-4     Document Type: Article

References (56)

1. Omura T. Heme-thiolate proteins. Biochem Biophys Res Commun. 2005;338:404-9.
2. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997;29:413-580.
3. Alterman MA, Hanzlik RP. Hydroxylation of fatty acids by microsomal and reconstituted cytochrome P450 2B1. FEBS Lett. 2002;512:319-22.
4. Janocha S, Schmitz D, Bernhardt R. Terpene hydroxylation with microbial cytochrome P450 monooxygenases. Adv Biochem Eng Biotechnol. 2015;148:215-50.
5. Lyu C, Zhou W, Zhang Y, Zhang S, Kou F, Wei H, Zhang N, Zuo Z. Identification and characterization of in vitro and in vivo metabolites of steroidal alkaloid veratramine. Biopharm Drug Dispos. 2015;36:308-24.
6. Song L, Laureti L, Corre C, Leblond P, Aigle B, Challis GL. Cytochrome P450-mediated hydroxylation is required for polyketide macrolactonization in stambomycin biosynthesis. J Antibiot (Tokyo). 2014;67:71-6.
7. Takahashi S, Nagano S, Nogawa T, Kanoh N, Uramoto M, Kawatani M, Shimizu T, Miyazawa T, Shiro Y, Osada H. Structure-function analyses of cytochrome P450revl involved in reveromycin A biosynthesis and evaluation of the biological activity of its substrate, reveromycin T. J Biol Chem. 2014;289:32446-58.
8. Narhi LO, Fulco AJ. Identification and characterization of two functional domains in cytochrome P-450BM-3, a catalytically self-sufficient monooxygenase induced by barbiturates in Bacillus megaterium. J Biol Chem. 1987;262:6683-90.
9. Whitehouse CJ, Bell SG, Wong LL. P450(BM3) (CYP102A1): connecting the dots. Chem Soc Rev. 2012;41:1218-60.
10. Narhi LO, Fulco AJ. Characterization of a catalytically self-sufficient 119,000-dalton cytochrome P-450 monooxygenase induced by barbiturates in Bacillus megaterium. J Biol Chem. 1986;261:7160-9.
11. Appel D, Lutz-Wahl S, Fischer P, Schwaneberg U, Schmid RD. A P450 BM-3 mutant hydroxylates alkanes, cycloalkanes, arenes and heteroarenes. J Biotechnol. 2001;88:167-71.
12. Carmichael AB, Wong LL. Protein engineering of Bacillus megaterium CYP102. The oxidation of polycyclic aromatic hydrocarbons. Eur J Biochem. 2001;268:3117-25.
13. Kim DH, Kim KH, Kim DH, Liu KH, Jung HC, Pan JG, Yun CH. Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3. Drug Metab Dispos. 2008;36:2166-70.
14. Kim DH, Ahn T, Jung HC, Pan JG, Yun CH. Generation of the human metabolite piceatannol from the anticancer-preventive agent resveratrol by bacterial cytochrome P450 BM3. Drug Metab Dispos. 2009;37:932-6.
15. Kim KH, Kang JY, Kim DH, Park SH, Kim D, Park KD, Lee YJ, Jung HC, Pan JG, Ahn T, Yun CH. Generation of human chiral metabolites of simvastatin and lovastatin by bacterial CYP102A1 mutants. Drug Metab Dispos. 2011;39:140-50.
16. Pandey RP, Parajuli P, Koffas MA, Sohng JK. Microbial production of natural and non-natural flavonoids: pathway engineering, directed evolution and systems/synthetic biology. Biotechnol Adv. 2016. doi: 10.1016/j.biotechadv.2016.02.012.
17. Pietta PG. Flavonoids as antioxidants. J Nat Prod. 2000;63:1035-42.
18. Cushnie TP, Lamb AJ. Antimicrobial activity of flavonoids. Int J Antimicrob Agents. 2005;26:343-56.
19. Pan MH, Lai CS, Ho CT. Anti-inflammatory activity of natural dietary flavonoids. Food Funct. 2010;1:15-31.
20. Zhu W, Jia Q, Wang Y, Zhang Y, Xia M. The anthocyanin cyanidin-3-O-β-glucoside, a flavonoid, increases hepatic glutathione synthesis and protects hepatocytes against reactive oxygen species during hyperglycemia: involvement of a cAMP-PKA-dependent signaling pathway. Free Radic Biol Med. 2012;52:314-27.
21. Ravishankar D, Rajora AK, Greco F, Osborn HM. Flavonoids as prospective compounds for anti-cancer therapy. Int J Biochem Cell Biol. 2013;45:2821-31.
22. Lin Y, Yan Y. Biotechnological production of plant-specific hydroxylated phenylpropanoids. Biotechnol Bioeng. 2014;111:1895-9.
23. Esaki H, Kawakishi S, Morimitsu Y, Osawa T. New potent antioxidative o-dihydroxyisoflavones in fermented Japanese soybean products. Biosci Biotechnol Biochem. 1999;63:1637-9.
24. Lee DE, Lee KW, Byun S, Jung SK, Song N, Lim SH, Heo YS, Kim JE, Kang NJ, Kim BY, Bowden TG, Bode AM, Lee HJ, Dong Z. 7,3',4'-Trihydroxyisoflavone, a metabolite of the soy isoflavone daidzein, suppresses ultraviolet B-induced skin cancer by targeting Cot and MKK4. J Biol Chem. 2011;286:14246-56.
25. Lo YL, Wanga W, Ho CT. 7,3,4-Trihydroxyisoflavone modulates multidrug resistance transporters and induces apoptosis via production of reactive oxygen species. Toxicology. 2012;302:221-32.
26. Nasr-Bouzaiene N, Sassi A, Bedoui A, Krifa M, Chekir-Ghedira L, Ghedira K. Immunomodulatory and cellular antioxidant activities of pure compounds from Teucrium ramosissimum Desf. Tumour Biol. 2016;37:7703-12.
27. Bodduluru LN, Kasala ER, Madhana RM, Barua CC, Hussain MI, Haloi P, Borah P. Naringenin ameliorates inflammation and cell proliferation in benzo(a)pyrene induced pulmonary carcinogenesis by modulating CYP1A1, NFΚB and PCNA expression. Int Immunopharmacol. 2016;30:102-10.
28. Nakajima VM, Madeira JV Jr, Macedo GA, Macedo JA. Biotransformation effects on anti lipogenic activity of citrus extracts. Food Chem. 2016;197:1046-53.
29. Pandey RP, Gurung RB, Sohng JK. Dietary sources, bioavailability and biological activities of naringenin and its derivatives. In: Stacks NM, editor. Apigenin and naringenin: natural sources, pharmacology and role in cancer prevention. New York: Nova Science Publishers; 2015. p. 151-72.
30. Kim DH, Kim BG, Lee Y, Ryu JY, Lim Y, Hur HG, Ahn JH. Regiospecific methylation of naringenin to ponciretin by soybean O-methyltransferase expressed in Escherichia coli. J Biotechnol. 2005;119:155-62.
31. Malla S, Pandey RP, Kim BG, Sohng JK. Regiospecific modifications of naringenin for astragalin production in Escherichia coli. Biotechnol Bioeng. 2013;110:2525-35.
32. Pandey RP, Gurung RB, Parajuli P, Koirala N, Tuoi LT, Sohng JK. Assessing acceptor substrate promiscuity of YjiC-mediated glycosylation toward flavonoids. Carbohydr Res. 2014;393:26-31.
33. Kasai N, Ikushiro S, Hirosue S, Arisawa A, Ichinose H, Wariishi H, Ohta M, Sakaki T. Enzymatic properties of cytochrome P450 catalyzing 3-hydroxylation of naringenin from the white-rot fungus Phanerochaete chrysosporium. Biochem Biophys Res Commun. 2009;387:103-8.
34. Kaltenbach M, Schröder G, Schmelzer E, Lutz V, Schröder J. Flavonoid hydroxylase from Catharanthus roseus: cDNA, heterologous expression, enzyme properties and cell-type specific expression in plants. Plant J. 1999;19:183-93.
35. Amor IL, Hehn A, Guedone E, Ghedira K, Engasser JM, Chekir-Ghedrira L, Ghoul M. Biotransformation of naringenin to eriodictyol by Saccharomyces cerevisiae functionally expressing flavonoid 3 hydroxylase. Nat Prod Commun. 2010;5:1893-8.
36. Estabrook RW. A passion for P450s (rememberances of the early history of research on cytochrome P450). Drug Metab Dispos. 2003;31:1461-73.
37. Pillai BV, Swarup S. Elucidation of the flavonoid catabolism pathway in Pseudomonas putida PML2 by comparative metabolic profiling. Appl Environ Microbiol. 2002;68:143-51.
38. Pan YG, Li YX, Yuan MQ. Isolation, purification and identification of etiolation substrate from fresh-cut Chinese water-chestnut (Eleocharis tuberosa). Food Chem. 2015;186:119-22.
39. Cao H, Chen X, Jassbi AR, Xiao J. Microbial biotransformation of bioactive flavonoids. Biotechnol Adv. 2015;33:214-23.
40. Park SH, Kim DH, Kim D, Kim DH, Jung HC, Pan JG, Ahn T, Kim D, Yun CH. Engineering bacterial cytochrome P450 (P450) BM3 into a prototype with human P450 enzyme activity using indigo formation. Drug Metab Dispos. 2010;38:732-9.
41. Stjernschantz E, van Vugt-Lussenburg BM, Bonifacio A, de Beer SB, van der Zwan G, Gooijer C, Commandeur JN, Vermeulen NP, Oostenbrink C. Structural rationalization of novel drug metabolizing mutants of cytochrome P450 BM3. Proteins. 2008;71:336-52.
42. Graham-Lorence S, Truan G, Peterson JA, Falck JR, Wei S, Helvig C, Capdevila JH. An active site substitution, F87V, converts cytochrome P450 BM-3 into a regio- and stereoselective (14S,15R)-arachidonic acid epoxygenase. J Biol Chem. 1997;272:1127-35.
43. Uppada V, Bhaduri S, Noronha SB. Cofactor regeneration-an important aspect of biocatalysis. Curr Sci. 2014;106:946-57.
44. Perez-Zabaleta M, Sjöberg G, Guevara-Martínez M, Jarmander J, Gustavsson M, Quillaguamán J, Larsson G. Increasing the production of (R)-3-hydroxybutyrate in recombinant Escherichia coli by improved cofactor supply. Microb Cell Fact. 2016;15:91.
45. Boghigian BA, Seth G, Kiss R, Pfeifer BA. Metabolic flux analysis and pharmaceutical production. Metab Eng. 2010;12:81-95.
46. Chemler JA, Fowler ZL, McHugh KP, Koffas MA. Improving NADPH availability for natural product biosynthesis in Escherichia coli by metabolic engineering. Metab Eng. 2010;12:96-104.
47. Mori A, Nishino C, Enoki N, Tawata S. Antibacterial activity and mode of action of plant flavonoids against Proteus vulgaris and Staphylococcus aureus. Phytochemistry. 1987;26:2231-4.
48. Li CZ, Jin HH, Sun HX, Zhang ZZ, Zheng JX, Li SH, Han SH. Eriodictyol attenuates cisplatin-induced kidney injury by inhibiting oxidative stress and inflammation. Eur J Pharmacol. 2016;772:124-30.
49. van Vugt-Lussenburg BM, Stjernschantz E, Lastdrager J, Oostenbrink C, Vermeulen NP, Commandeur JN. Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis. J Med Chem. 2007;50:455-61.
50. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes I. Evidence for its hemoprotein nature. J Biol Chem. 1964;239:2370-8.
51. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.
52. Pandey RP, Malla S, Simkhada D, Kim BG, Sohng JK. Production of 3-O-xylosyl quercetin in Escherichia coli. Appl Microbiol Biotechnol. 2013;97:1889-901.
53. Kuppusamy P, Yusoff MM, Parine NR, Govindan N. Evaluation of in vitro antioxidant and antibacterial properties of Commelina nudiflora L. extracts prepared by different polar solvents. Saudi J Biol Sci. 2015;22:293-301.
54. Jung HJ, Lee HB, Lim CH, Kim CJ, Kwon HJ. Cochlioquinone A1, a new anti-angiogenic agent from Bipolaris zeicola. Bioorg Med Chem. 2003;11:4743-7.
55. Bhattarai S, Liou K, Oh TJ. Homology modeling and docking studies of Streptomyces peucetius CYP147F1 as limonene hydroxylase. J Microbiol Biotechnol. 2012;22:917-22.
56. Venkatachalam CM, Jiang X, Oldfield T, Waldman M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model. 2003;21:289-307.